Thermo Fisher Scientific is showcasing new capabilities in AI-enabled research, clinical development, and advanced manufacturing at BIO International 2026. The company announced strategic investments and partnerships designed to help biopharma customers advance innovation, simplify complex workflows, and bring therapies to patients faster. These initiatives reinforce Thermo Fisher’s role as a provider of integrated solutions across the drug development lifecycle.

Pharma Services and Advanced Manufacturing

Thermo Fisher is expanding its global manufacturing capacity to support biologics, sterile fill-finish, oral solid dose manufacturing, and integrated device assembly. Recent investments include:

Clinical Research and Data Intelligence

The company is advancing clinical development through expanded digital capabilities and acquisitions. Thermo Fisher completed the acquisition of Clario Holdings Inc., adding endpoint data and evidence generation solutions that have supported approximately 70% of FDA and EMA novel drug approvals over the past decade. Strategic collaborations with HealthVerity and Datavant aim to advance real-world evidence and trial optimization. Additionally, AI-enabled analytics and workflow solutions are being deployed to improve clinical trial efficiency and decision-making.

AI-Enabled Research and Scientific Workflows

Thermo Fisher is leveraging strategic relationships with NVIDIA, OpenAI, TetraScience, and BenchSci to enhance AI-enabled scientific workflows. These partnerships help customers automate laboratory workflows, unify scientific data, and generate deeper insights. Through the Accelerator Drug Development program, the company supports emerging biotech companies in combining scientific expertise with AI-enabled workflows. Recent software acquisitions, including MSAID and Proteinaceous, strengthen the proteomics ecosystem by adding AI and machine learning capabilities for interpreting complex datasets.

Scientific Innovation and Enabling Technologies

New workflow innovations include the Applied Biosystems PowerFlex Thermal Cycler and the Gibco CTS Compleo Fill and Finish System. The company also unveiled the Gibco CTS DynaXS Single Use Bioreactor for scalable cell therapy manufacturing and launched the Gibco CHOvantage GS Cell Line Development Kit to streamline timelines and support scalable manufacturing.

Thermo Fisher Scientific has outperformed the market over the past 15 years by 1.73% on an annualized basis, producing an average annual return of 14.21%. The company currently holds a market capitalization of $174.33 billion.

Investment Growth

If an investor had bought $100 of Thermo Fisher Scientific stock 15 years ago, it would be worth $743.26 today based on a price of $462.10 at the time of writing.

Performance Metrics

The following table outlines the key performance figures for Thermo Fisher Scientific over the last 15 years:

The key insight from this data is the significant impact compounded returns can have on cash growth over an extended period.